Rachel Haurwitz, Caribou Biosciences CEO
April 5, 2024 04:58 AM EDTUpdated 10:33 AM
R&D
Cell/Gene Tx

‘Look be­fore you leap’: Cari­bou to start Ph1 au­toim­mune study of CAR-T ther­a­py

Lei Lei Wu

News Reporter

Just like oth­er cell ther­a­py com­pa­nies, Cari­bou Bio­sciences is en­ter­ing the au­toim­mune dis­ease field.

The Berke­ley, CA-based biotech dis­closed Thurs­day af­ter­noon …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Gen­mab chops ear­ly can­cer prospects to pri­or­i­tize Phase 3 projects

De­nali teas­es ear­ly da­ta for en­zyme re­place­ment ther­a­py in rare dis­ease

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times